Anti-TNF therapy controls the inflammatory manifestations preventing the occurrence of vascular events in patients.2 Antiplatelet agents and anticoagulants are controversial, as they may increase the risk of haemorrhagic strokes.3 Hence, we discontinued antiplatelet agents once the diagnosis was confirmed. This evidence concerns the gene TNF and hemorrhagic stroke.